The Synthetic Biology Revolution Reshaping the Pharmaceutical Industry Landscape – An In-Depth Analysis of Biotech Trends in 2026
Editor
In 2026, the biopharmaceutical industry is undergoing unprecedented changes due to the convergence of artificial intelligence and synthetic biology. According to the latest report from global market research firm McKinsey, the global biopharmaceutical market size reached $124 billion in 2025 and is expected to grow at a CAGR of 12.8%, reaching $220 billion by 2030. The key drivers of this rapid growth are the commercialization of AI-based drug discovery platforms and synthetic biology technologies. Particularly, the personalized medicine market, which gained momentum in Q4 2025, is fundamentally transforming the industry structure that was previously centered around blockbuster drugs.
The most notable technology in the field of synthetic biology is Programmable Biology. This technology involves designing and editing the DNA of organisms like computer code to create biological systems that perform desired functions. The automated platform developed by Ginkgo Bioworks, based in Boston, USA, achieved a throughput of testing 50,000 genetic variants per month as of 2025. This is 100 times faster than traditional laboratory methods. Samsung Biologics, based in Incheon, Korea, formed a strategic partnership with Ginkgo in September 2025 to introduce the Programmable Biology platform to Asia for the first time. As a result, they plan to offer customized biopharmaceutical production services starting in the first half of 2026.
In the AI-based drug development sector, DeepMind’s AlphaFold technology is acting as a game-changer. AlphaFold 3.0, released in December 2025, increased protein structure prediction accuracy to 95.2%. This innovation reduces research time from 10 years to 6 months compared to traditional experimental methods. Roche, based in Basel, Switzerland, initiated Phase 1 clinical trials in November 2025 for its first drug candidate, RO-7496998, utilizing AlphaFold 3.0. This drug, aimed at treating Alzheimer’s disease, features a novel mechanism that prevents abnormal tau protein folding, unlike existing amyloid-beta-targeting treatments.
AI Investment Race Among Global Pharmaceutical Companies
Traditional large pharmaceutical companies are rapidly expanding their investments in AI technology. Johnson & Johnson, based in New Jersey, USA, invested a total of $4.5 billion in AI drug development in 2025, accounting for 32% of its total R&D budget. Janssen Pharmaceuticals, a division of Johnson & Johnson, drew industry attention when an immuno-oncology drug, co-developed with Exscientia, an AI startup based in Cambridge, UK, achieved a response rate of over 50% in Phase 2 clinical trials in January 2026. This significantly exceeds the average response rate of 25-30% for existing immuno-oncology drugs.
Pfizer, based in New York, is also focusing on strengthening its AI-based drug development capabilities. In August 2025, Pfizer acquired the Computational Medicine Development (CMD) platform, which analyzes patient-specific genetic and clinical data to propose optimal treatments. The first achievement using this platform was a next-generation targeted therapy, PF-07321332, for cancer patients resistant to existing treatments, which showed that 78% of patients experienced disease progression inhibition for over six months in clinical trials. This is a 40% improvement over existing treatments for the same indication.
In the European market, Novartis, based in Basel, Switzerland, is leading the way. Novartis invested $1.2 billion in its own AI research lab, the Novartis Institutes for BioMedical Research (NIBR), in 2025 to significantly expand its AI-based drug development pipeline. The company is particularly excelling in the rare disease sector, with an improved version of the AI-designed gene therapy Zolgensma receiving FDA approval in December 2025. This therapy reduces side effects by 60% while maintaining equivalent therapeutic efficacy compared to existing treatments.
Rapid Growth in the Asian Market
The biopharmaceutical market in the Asia region was valued at $42 billion in 2025, growing by 18.5% compared to the previous year. Korea and China are leading this growth. Celltrion, based in Incheon, Korea, recorded $2.7 billion in biosimilar sales in 2025, capturing a 12.3% share of the global biosimilar market. Celltrion’s Remsima (infliximab biosimilar) continues to expand its market share in Europe with a 65% price competitiveness compared to the original drug Remicade.
In the Chinese market, Biogen China, based in Shanghai, obtained exclusive sales rights for the Alzheimer’s treatment Aducanumab in China and began full-scale market entry in the second half of 2025. The potential market size targeting China’s 150 million elderly population is estimated at $18 billion annually. Simultaneously, Baidu Bio, the AI subsidiary of Baidu based in Beijing, discovered a total of 23 new drug candidates through its self-developed drug discovery platform ‘LinBo’ in 2025. Three of these candidates have already entered Phase 1 clinical trials, demonstrating the potential for AI drug development in China.
In Japan, Takeda Pharmaceutical, based in Tokyo, formed a strategic alliance with Gilead Sciences, based in California, USA, in September 2025. The core of this alliance is the development of next-generation HIV treatments combining Takeda’s Asian market network with Gilead’s antiviral technology. The companies plan to start global Phase 3 clinical trials for a long-acting HIV treatment in the first half of 2026, which innovatively improves the administration method from daily oral intake to a monthly injection.
In the biopharmaceutical manufacturing sector, Samsung Biologics in Korea has established a dominant position in the global CDMO (Contract Development and Manufacturing Organization) market. Samsung Biologics’ revenue reached $2.3 billion in 2025, a 28% increase from the previous year. With the completion of its fourth plant, the total production capacity reached 360,000 liters, making it the world’s largest biopharmaceutical production facility. As of January 2026, Samsung Biologics’ order backlog stands at $15.6 billion, securing a stable growth foundation for the next five years.
Looking at investment trends, global venture capital investment in the biopharmaceutical sector totaled $24.7 billion in 2025. Of this, AI-based drug development accounted for $8.9 billion (36%), the largest share. A notable investment case is Moderna, based in Boston, USA, which is developing mRNA-based personalized cancer vaccines. This technology involves creating customized mRNA vaccines by analyzing the tumor genetics of individual patients, and in Phase 2 clinical trials in 2025, it reduced the recurrence rate of melanoma patients by 44%. Consequently, Moderna secured an additional $1.5 billion in investment in December 2025.
Changes in the regulatory environment also significantly impact industry development. In May 2025, the US FDA released ‘AI-Based Drug Development Guidelines,’ clarifying the approval process for AI-designed drugs. According to these guidelines, clinical trial periods can be reduced by up to 30% if AI algorithms meet transparency and verifiability conditions. The European Medicines Agency (EMA) also introduced similar guidelines in September 2025, advancing global regulatory standardization. The Korean Ministry of Food and Drug Safety plans to introduce a special review system for AI drug development in the first half of 2026.
In summary, the biopharmaceutical industry in 2026 is at a turning point where technological innovation and market expansion are occurring simultaneously. According to McKinsey’s latest analysis, the introduction of AI and synthetic biology technologies is expected to reduce drug development costs by an average of 35% and shorten development periods by 40%. This innovation reduces the traditional 10-15 year drug development process to 6-9 years. Simultaneously, the personalized medicine market is expected to grow rapidly from $28 billion in 2026 to $85 billion by 2030, with an annual growth rate of 32%. These changes are transitioning the pharmaceutical industry structure from a blockbuster-centered model to a multi-product, small-batch production system, offering new opportunities particularly for Asian biotech companies.
The information provided in this article is for analytical purposes only and is not an investment solicitation or advice. Please consult a professional before making investment decisions.
